Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA70112, USA.
Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA70112, USA; Cell and Immunobiology, and R & D Center for Cancer Therapeutics, National Cancer Center, Goyang 410-769, Korea.
BMB Rep. 2014 Mar;47(3):122-9. doi: 10.5483/bmbrep.2014.47.3.283.
Although considerable progress has been made in understanding how tumors evade immune surveillance, measures to counter the same have not kept pace with the advances made in designing effective strategies. 4-1BB (CD137; TNFRS9), an activation-induced costimulatory molecule, is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand (4-1BBL) has important implications in many clinical conditions, including cancer. In depth analysis revealed that 4-1BB-mediated anti-cancer effects are based on its ability to induce activation of cytotoxic T lymphocytes (CTL), and among others, high amounts of IFN-γ. In this review, we will discuss the various aspects of 4-1BB-mediated anti-tumor responses, the basis of such responses, and future directions.
尽管在理解肿瘤如何逃避免疫监视方面已经取得了相当大的进展，但对抗肿瘤的措施并没有跟上设计有效策略的进展。4-1BB（CD137；TNFRS9）是一种激活诱导的共刺激分子，是免疫反应的重要调节剂。针对 4-1BB 或其天然配体 4-1BB 配体（4-1BBL）在许多临床情况下都具有重要意义，包括癌症。深入分析表明，4-1BB 介导的抗癌作用基于其诱导细胞毒性 T 淋巴细胞（CTL）激活的能力，以及其他因素，如大量 IFN-γ。在这篇综述中，我们将讨论 4-1BB 介导的抗肿瘤反应的各个方面、这种反应的基础以及未来的方向。
